Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2008

View Archived Issues

Sirion and Bridge enter agreement for topical ophthalmic drugs containing norketotifen

Novel HDAC8-specific inhibitor profiled at Pharmacyclics

GSK received CHMP positive opinion for H5N1 influenza vaccine

Fusion protein shows promise as influenza vaccine in preclinical studies

Schering-Plough: Q4 and full-year 2007 highlights

Inhibition of QseC signaling, a potential new strategy against tularemia infection

Novel agents for metabolic disorders reported in recent patent literature

Elan reviews recent pipeline developments

Positive preclinical results of S-0139 in ischemic stroke

FDA accepts and grants priority review to Eurand's NDA for Zentase for pancreatitis

FDA accepts for review Forest and Cypress' NDA for milnacipran for fibromyalgia

FDA cancels February 2008 Advisory Committee meeting to discuss Theravance's telavancin

GPC outlines development plans for its oncology program

Hyperion Therapeutics begins enrollment in phase II trial of Ammonul for hepatic encephalopathy

HVTN to initiate phase IIa human trials of GeoVax's DNA and MVA HIV/AIDS vaccines

InteKrin Therapeutics initiates phase IIb study of INT-131 in type 2 diabetes

Sciele enters three-year agreement with sanofi-aventis to market Allegra in the U.S.

Recent patents disclose novel therapeutics for arthritis

GlaxoSmithKline patent describes new agents for diabetes and related disorders

Marillion and Cytokine enter license agreement for Pilobuc buccal insert for xerostomia

Argenta initiates phase II ADC-4022 trial in COPD and severe asthma

First patient treated with anticancer drug TRC-102 in phase I trial

Patient recruitment finalized for Moberg Derma's phase III K-101 trial

PBT-2 shows safety and tolerability in patients with early Alzheimer's disease

EMEA accepts MAA for tolvaptan in worsening heart failure and hyponatremia

FDA accepts Duramed's Lo Seasonique NDA for filing

PX-478 is effective in preclinical mouse model of human lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...